Solana (NASDAQ:HSDT) Issues Earnings Results

Solana (NASDAQ:HSDT) announced its quarterly earnings data on Friday. The company reported ($1.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.96), FiscalAI reports. Solana had a negative net margin of 679.54% and a negative return on equity of 104.96%. The business had revenue of $3.62 million during the quarter, compared to analysts’ expectations of $3.40 million.

Here are the key takeaways from Solana’s conference call:

• Solana Company said first-quarter revenue rose to $3.6 million from just $49,000 a year ago, driven mainly by $3.4 million of staking revenue. Management framed this as early validation of its digital asset treasury strategy.
• The company reported a net loss of $99.8 million, largely due to non-cash markdowns tied to the roughly 33% decline in SOL during the quarter. It also recorded an $89.2 million unrealized loss on digital assets and receivables.
• Management highlighted 6.9% average net staking yield in Q1, above the estimated system-wide average of about 6.0%. They said this outperformance came from validator selection, MEV capture, and active rebalancing.
• The company completed an $8 million strategic equity raise in late April at a price described as about 1.1x NAV, and said part of the proceeds was used to buy SOL at attractive levels. Management called the raise immediately accretive to SOL per share.
• Solana Company is expanding beyond treasury management into advisory services, validator infrastructure, and an AI-powered platform, with initial validator nodes expected to go live in late June. Management also said it completed the divestiture of its medical device business, which should help reduce future costs.

Solana Price Performance

NASDAQ:HSDT traded down $0.09 during trading hours on Friday, reaching $2.30. 147,829 shares of the company traded hands, compared to its average volume of 216,834. The firm’s 50-day moving average is $2.06 and its 200-day moving average is $2.92. The stock has a market cap of $126.25 million, a P/E ratio of 0.00 and a beta of 1.06. Solana has a 1-year low of $1.59 and a 1-year high of $258.50.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on HSDT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a report on Tuesday, April 21st. Zacks Research raised Solana to a “hold” rating in a report on Monday, April 27th. Maxim Group started coverage on Solana in a report on Monday, April 6th. They issued a “buy” rating and a $4.00 price objective on the stock. Finally, B. Riley Financial assumed coverage on Solana in a report on Thursday, April 23rd. They issued a “buy” rating and a $3.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Solana presently has an average rating of “Moderate Buy” and an average target price of $3.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HSDT. Price T Rowe Associates Inc. MD acquired a new stake in Solana in the 4th quarter valued at $46,000. OMERS ADMINISTRATION Corp acquired a new stake in Solana in the 4th quarter valued at $88,000. Aristides Capital LLC acquired a new stake in Solana in the 4th quarter valued at $137,000. XTX Topco Ltd acquired a new stake in Solana in the 4th quarter valued at $140,000. Finally, Marshall Wace LLP acquired a new stake in Solana in the 4th quarter valued at $195,000. Hedge funds and other institutional investors own 18.63% of the company’s stock.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.